Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting

View through CrossRef
Context: Several studies have reported that PD-L1 has shown therapeutic activity in various tumor types. However, its expression changes in a person on administration of NAC which is reported by very few studies. Aims: To find out the difference in the expression of PD-L1 by tumor cells after the administration of NAC. Settings and Design: This prospective study was conducted on 30 patients who were diagnosed with locally advanced breast carcinoma (LABC) between 2017 and 2019 and those who received NAC followed by surgery. Methods and Material: Breast cancer specimens were collected using core needle biopsy prior to administration of NAC and IHC was performed. Frequency and staining intensity of PD-L1 by tumor cells were analyzed. PD-L1 expression was dichotomized into two groups according to the frequency distributions of the H-scores. Statistical Analysis Used: The differences in expression of PD-L1 along with various parameters were analyzed using Chi-square test and Student's t test. Results: The mean age of the patients in our study was 51.37 ± 11.37 years. The response of NAC according to the RECIST criteria showed that most of patients (83.3%) showed complete response. Of the 30 cases, 11 (36.7%) patients were PD-L1 positive before the administration of NAC. We found a significant change in expression from positive to negative status, i.e., seven patients changed from positive to negative ( p = 0.036). Upon comparing the PD-L1 expression before NAC, significant association was observed between the primary tumor (T) and tumor stage with high PD-L1 expression ( p = 0.020 and P = 0.034). After NAC, 18 (69.2%) patients who were ER positive and 18 (69.2%) patients who were PR positive showed negative PD-L1 expression while none of them were positive in PD-L1 positive patients ( p = 0.018 and P = 0.018). Conclusion: PD-L1 expression in a same person changes upon administration of NAC which may indirectly be used as a predictor of response to NAC.
Title: Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
Description:
Context: Several studies have reported that PD-L1 has shown therapeutic activity in various tumor types.
However, its expression changes in a person on administration of NAC which is reported by very few studies.
Aims: To find out the difference in the expression of PD-L1 by tumor cells after the administration of NAC.
Settings and Design: This prospective study was conducted on 30 patients who were diagnosed with locally advanced breast carcinoma (LABC) between 2017 and 2019 and those who received NAC followed by surgery.
Methods and Material: Breast cancer specimens were collected using core needle biopsy prior to administration of NAC and IHC was performed.
Frequency and staining intensity of PD-L1 by tumor cells were analyzed.
PD-L1 expression was dichotomized into two groups according to the frequency distributions of the H-scores.
Statistical Analysis Used: The differences in expression of PD-L1 along with various parameters were analyzed using Chi-square test and Student's t test.
Results: The mean age of the patients in our study was 51.
37 ± 11.
37 years.
The response of NAC according to the RECIST criteria showed that most of patients (83.
3%) showed complete response.
Of the 30 cases, 11 (36.
7%) patients were PD-L1 positive before the administration of NAC.
We found a significant change in expression from positive to negative status, i.
e.
, seven patients changed from positive to negative ( p = 0.
036).
Upon comparing the PD-L1 expression before NAC, significant association was observed between the primary tumor (T) and tumor stage with high PD-L1 expression ( p = 0.
020 and P = 0.
034).
After NAC, 18 (69.
2%) patients who were ER positive and 18 (69.
2%) patients who were PR positive showed negative PD-L1 expression while none of them were positive in PD-L1 positive patients ( p = 0.
018 and P = 0.
018).
Conclusion: PD-L1 expression in a same person changes upon administration of NAC which may indirectly be used as a predictor of response to NAC.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Abstract Introduction: Granulomatous mastitis (GM) is a rare inflammatory breast disease that mimics carcinoma. GM can coexist with breast cancer (BC), though the relationship rema...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract Introduction  Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract P1-10-28: Role of Sec62 in prediction of response to neoadjuvant chemotherapy in patients with primary breast cancer
Abstract P1-10-28: Role of Sec62 in prediction of response to neoadjuvant chemotherapy in patients with primary breast cancer
Abstract Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3...

Back to Top